http://www.hv-info.ru/info/ki/gep-b-d/295-myrcludex-b.html
"Mirkludeks B» (Myrcludex B)
Updated 10/16/2012 18:50
"Mirkludeks B» (Myrcludex B)
Resolution № 231
Name of organization conducting clinical trials: LLC "Gepatera"
The goal of clinical research: The study of therapeutic efficacy of three different doses of the drug Mirkludeks B (selection of optimal dose of the drug), and its clinical safety, namely the assessment of changes in the level of HBsAg under the influence of treatment with 3 different doses of the drug evaluation virologic response to treatment (level HBV DNA), biochemical response to treatment, and to study the pharmacokinetic profile and immunogenicity of the drug in patients with HBeAg-negative chronic hepatitis B
Start 08/13/2012
Ending 31/12/2013
The list of medical institutions, which are intended for clinical research
1.Gosudarstvennoe institution Moscow Regional Research Clinical Institute. MF Vladimir, 129110, Moscow, ul. Shchepkin, 61/2, tel. (495) 681 55 85
2. Public health agency of Moscow "Infectious Clinical Hospital № 2 Moscow Health Department", 105275, Moscow, 8th Street Mount Falcon, 15
3. Federal State Institution "Scientific Research Institute of Influenza," the Ministry of Health and Social Development of the Russian Federation, 197376, St. Petersburg, ul. Prof. Popov St., 15/17
4. State budget institution of higher education "Chelyabinsk State Medical Academy" of the Ministry of Health and Social Development of the Russian Federation (Chelyabinsk)., Address infectious department № 2 and infectious services clinic: 454052, Russia, Chelyabinsk, ul. Cherkassy, 2., 454092, Russia, Chelyabinsk, ul. Thievish, 64
5. Limited Liability Medical Company "Hepatologist" 443011, Samara, October district, st. Glade 3, D. 157, tel. (846) 926 20 26
6. St. Petersburg State health agency "Center for Prevention and Control of AIDS and infectious diseases", 190103, St. Petersburg, nab. Bypass channel, 179
7. State health agency "Sverdlovsk Regional Hospital N 1" GOOSE "SOKB N 1", 620102, Ekaterinburg, ul.Volgogradskaya, 185.
8. Public health agency of Moscow "Central Research Institute of Gastroenterology," Moscow Health Department, 111123, Moscow, road enthusiasts, 86, tel. (495) 304 19 42
9. State Organization of Health of Moscow "City Clinical Hospital № 24" Moscow Health Department, 127015, st. Scribe, 10 10. Limited Liability Company "MedElitKonsalting", 121107, Moscow, Victory Square, 2, block 2
i agree totally
it is useless to just post our own fantasy here!we have to post only the studies with their results and of course never ever make confusion like this with fantasy
at the moment only antivirals for many many years 5-7years and then intf add on has shown hbv clearance and is available in most countries and this is what we can do to get cured today
For the record, there is no evidence to support the following statements:
"From what I have heard it will registered in 2015 for use. And from what is reported it clears HBV with interferon also in like 2 months of therapy. Efficacy rate is close to 100%. "
They are just someone's imaginations. Please wait for the results of the clinical trial and hope for the best.
If Nasvac in Phase III trail ..than it must be release in 2013..to save the life of million's people who are looking towards this vaccination...
In the interest of fact: there is NO COMBINATION of NASVAC and Pegylated Interferon 2b BEING TESTED! Pegylated Interferon 2b is the control or "placebo" arm of the trial.
Active Comparator: Pegylated Interferon 2b
Active Comparator: HBsAg and HBcAg combination
Yes you are correct it will stimulate antibody production in us http://clinicaltrials.gov/ct2/show/NCT01374308 looks like in stage 3 they will look at giving it together with interferon to stimulate antibodies production.
this is a right approach at this to have a cost effective treatment.